# US 2019/0375727 A1 · 2-substituted aromatic ring-pyrimidine derivative and preparation and application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0375727 A1
- Document ID: US20190375727A1
- Status: Published application
- Kind: A1
- Application number: 16/348,502
- Filed: 2017-11-08
- Published: 2019-12-12
- Earliest claimed: 2016-11-10
- Assignees: Zhejiang University; Shanghai Institute of Materia Medica, Chinese Academy of Sciences
- Applicants: Zhejiang University; Shanghai Institute of Materia Medica, Chinese Academy of Sciences
- Inventors: Tao Liu; Jia Li; Yongzhou Hu; Yubo Zhou; Xiaowu Dong; Anhui Gao; Pinrao Song; Peipei Wang; Lexian Tong; Xiaobei Hu; Mingbo Su
- Web page: https://patentgrep.com/patent/US20190375727A1

## CPC

- C07D 401/14: containing three or more hetero rings
- A61P 35/00: Antineoplastic agents
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 403/14: containing three or more hetero rings
- C07D 405/14: containing three or more hetero rings
- C07D 409/14: containing three or more hetero rings
- C07D 413/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A 2-substituted aromatic ring-pyrimidine derivative as shown in a general formula I, and an optical isomer or a pharmaceutically acceptable salt or a solvate thereof are provided. The present invention designs and synthesizes a series of novel small molecular Chk1 inhibitors by using N-substituted pyridin-2-aminopyrimidine obtained through structure-based virtual screening as a lead compound, and carries out Chk1 kinase inhibitory activity test. The experiment confirmed that said compounds possess strong anti-cancer effect, Chk1 kinase inhibitory activity and are promising Chk1 inhibitors. The compounds can be used as new cancer therapeutic drugs, which can be applied to treat solid tumors or hematologic tumors related to proliferative disease of human or animal.

## Claims

### Claim at position 1

1: A 2-substituted aromatic ring-pyrimidine derivative, and an optical isomer or a pharmaceutically acceptable salt or a solvate thereof, wherein the 2-substituted aromatic ring-pyrimidine derivative has a structure as shown in a general formula I:
wherein ring A comprises 1 to 3 substituted or unsubstituted penta- or hexa-heterocyclic aryl selected from O, N and S; and a substituent is R4;
B is selected from —NH,
wherein B1 is selected from H, C1-4 alkyl, halogenated C1-4 alkyl, C1-4 alkoxy, and halogenated C1-4 alkoxy;
R1 is selected from halogen atom, C1-6 alkyl, halogenated C1-6 alkyl, C3-6 cycloalkyl, halogenated C3-6 cycloalkyl, C1-6 alkoxy, halogenated C1-6 alkoxy, C2-6 alkenyl, C2-6 hydroxy substituted alkenyl, C2-6 alkynyl, C2-6 hydroxy substituted alkynyl, and an unsubstituted or substituted penta- or hexa- aromatic ring or aromatic heterocyclic ring, wherein the aromatic heterocyclic ring comprises 1 to 3 hetero atoms selected from O, N and S, substitution is mono-, di- or tri-substitution, and a substituent is Ra;
Ra is selected from H, halogen, nitro, cyano, C1-3 alkyl, halogenated C1-3 alkyl, —C(═O)ORb, —C(═O)NHRb, —NHRb, —ORb, and —NHCORb; Rb is selected from H, C1-3 alkyl, halogenated C1-3 alkyl, C1-3 alkoxy, halogenated C1-3 alkoxy, and C1-7 alkylamine;
R2 is selected from H, —NHRc, —N(Rc)2, —ORc, and —SRc; Rc is selected from penta- to octa-aliphatic ring containing 1 to 3 heteroatoms selected from O and N, C1-7 alkyl, C1-7 hydroxyalkyl, C1-7 alkylamino, and C1-7 alkoxy;
R3 is selected from halogen, nitro, cyano, C1-3 alkyl, halogenated C1-3 alkyl, C1-3 alkoxy, halogenated C1-3 alkoxy, C1-3 alkylamino, and halogenated C1-3 alkylamino;
R4 is selected from H, halogen, nitro, cyano, trifluoromethyl, C1-3 alkyl, C1-3 alkoxy, amide, substituted alkyl amide.

### Claim at position 2 (depends on 1)

2: The 2-substituted aromatic ring-pyrimidine derivative, and the optical isomer or the pharmaceutically acceptable salt or the solvate thereof, as recited in claim 1, wherein the 2-substituted aromatic ring-pyrimidine derivative has a structure as shown in a general formula II:
wherein W, X, Y and Z are identical or different and are independently selected from N, C and O;
B is selected from —NH,
wherein B1 is selected from H, C1-4 alkyl, halogenated C1-4 alkyl, C1-4 alkoxy, and halogenated C1-4 alkoxy;
R1 is selected from halogen atom, C1-6 alkyl, halogenated C1-6 alkyl, C3-6 cycloalkyl, halogenated C3-6 cycloalkyl, C1-6 alkoxy, halogenated C1-6 alkoxy, C2-6 alkenyl, C2-6 hydroxy substituted alkenyl, C2-6 alkynyl, C2-6 hydroxy substituted alkynyl, and an unsubstituted or substituted penta- or hexa- aromatic ring or aromatic heterocyclic ring, wherein the aromatic heterocyclic ring comprises 1 to 3 hetero atoms selected from O, N and S, substitution is mono-, di- or tri-substitution, and a substituent is Ra;
Ra is selected from H, halogen, nitro, cyano, C1-3 alkyl, halogenated C1-3 alkyl, —C(═O)ORb, —C(═O)NHRb, —NHRb, —ORb, and —NHCORb; Rb is selected from H, C1-3 alkyl, halogenated C1-3 alkyl, C1-3 alkoxy, halogenated C1-3 alkoxy, and C1-7 alkylamine;
R2 is selected from H, —NHRc, —N(Rc)2, —ORc, and —SRc; Rc is selected from penta- to octa-aliphatic ring containing 1 to 3 heteroatoms selected from O and N, C1-7 alkyl, C1-7 hydroxyalkyl, C1-7 alkylamino, and C1-7 alkoxy;
R3 is selected from halogen, nitro, cyano, C1-3 alkyl, halogenated C1-3 alkyl, C1-3 alkoxy, halogenated C1-3 alkoxy, C1-3 alkylamino, and halogenated C1-3 alkylamino;
R4 is selected from H, halogen, nitro, cyano, trifluoromethyl, C1-3 alkyl, C1-3 alkoxy, amide, substituted alkyl amide.

### Claim at position 3 (depends on 1)

3: The 2-substituted aromatic ring-pyrimidine derivative, and the optical isomer or the pharmaceutically acceptable salt or the solvate thereof, as recited in claim 1, wherein the 2-substituted aromatic ring-pyrimidine derivative has a structure as shown in a general formula III:
wherein W, X, Y and Z are identical or different and are independently selected from N and C;
B is selected from —NH,
wherein B1 is selected from H, C1-4 alkyl, halogenated C1-4 alkyl, C1-4 alkoxy, and halogenated C1-4 alkoxy;
R1 is selected from halogen atom, C1-6 alkyl, halogenated C1-6 alkyl, C3-6 cycloalkyl, halogenated C3-6 cycloalkyl, C1-6 alkoxy, halogenated C1-6 alkoxy, C2-6 alkenyl, C2-6 hydroxy substituted alkenyl, C2-6 alkynyl, C2-6 hydroxy substituted alkynyl, and an unsubstituted or substituted penta- or hexa- aromatic ring or aromatic heterocyclic ring, wherein the aromatic heterocyclic ring comprises 1 to 3 hetero atoms selected from O, N and S, substitution is mono-, di- or tri-substitution, and a substituent is Ra;
Ra is selected from H, halogen, nitro, cyano, C1-3 alkyl, halogenated C1-3 alkyl, —C(═O)ORb, —C(═O)NHRb, —NHRb, —ORb, and —NHCORb; Rb is selected from H, C1-3 alkyl, halogenated C1-3 alkyl, C1-3 alkoxy, halogenated C1-3 alkoxy, and C1-7 alkylamine;
R2 is selected from H, —NHRc, —N(Rc)2, —ORc, and —SRc; Rc is selected from penta- to octa-aliphatic ring containing 1 to 3 heteroatoms selected from O and N, C1-7 alkyl, C1-7 hydroxyalkyl, C1-7 alkylamino, and C1-7 alkoxy;
R3 is selected from halogen, nitro, cyano, C1-3 alkyl, halogenated C1-3 alkyl, C1-3 alkoxy, halogenated C1-3 alkoxy, C1-3 alkylamino, and halogenated C1-3 alkylamino;
R4 is selected from H, halogen, nitro, cyano, trifluoromethyl, C1-3 alkyl, C1-3 alkoxy, amide, substituted alkyl amide.

### Claim at position 4 (depends on 2)

4: The 2-substituted aromatic ring-pyrimidine derivative, and the optical isomer or the pharmaceutically acceptable salt or the solvate thereof, as recited in claim 2, wherein the 2-substituted aromatic ring-pyrimidine derivative has a structure as shown in a general formula IV:
wherein W, X, Y and Z are identical or different and are independently selected from N, C and O;
R1 is selected from halogen atom, C1-6 alkyl, halogenated C1-6 alkyl, C3-6 cycloalkyl, halogenated C3-6 cycloalkyl, C1-6 alkoxy, halogenated C1-6 alkoxy, C2-6 alkenyl, C2-6 hydroxy substituted alkenyl, C2-6 alkynyl, C2-6 hydroxy substituted alkynyl, and an unsubstituted or substituted penta- or hexa- aromatic ring or aromatic heterocyclic ring, wherein the aromatic heterocyclic ring comprises 1 to 3 hetero atoms selected from O, N and S, substitution is mono-, di- or tri-substitution, and a substituent is Ra;
Ra is selected from H, halogen, nitro, cyano, C1-3 alkyl, halogenated C1-3 alkyl, —C(═O)ORb, —C(═O)NHRb, —NHRb, —ORb, and —NHCORb; Rb is selected from H, C1-3 alkyl, halogenated C1-3 alkyl, C1-3 alkoxy, halogenated C1-3 alkoxy, and C1-7 alkylamine;
R2 is selected from H, —NHRc, —N(Rc)2, —ORc, and —SRc; Rc is selected from penta- to octa-aliphatic ring containing 1 to 3 heteroatoms selected from O and N, C1-7 alkyl, C1-7 hydroxyalkyl, C1-7 alkylamino, and C1-7 alkoxy;
R3 is selected from halogen, nitro, cyano, C1-3 alkyl, halogenated C1-3 alkyl, C1-3 alkoxy, halogenated C1-3 alkoxy, C1-3 alkylamino, and halogenated C1-3 alkylamino;
R4 is selected from H, halogen, nitro, cyano, trifluoromethyl, C1-3 alkyl, C1-3 alkoxy, amide, substituted alkyl amide.

### Claim at position 5 (depends on 4)

5: The 2-substituted aromatic ring-pyrimidine derivative, and the optical isomer or the pharmaceutically acceptable salt or the solvate thereof, as recited in claim 4, wherein the derivative is selected from:
5-(1-methyl-1H-pyrazol-4-yl)-N2-(3-methylpyrazol-5-yl)-N4-(piperidin-4-yl)-2,4-diaminopyrimidine,
5-(1-methyl-1H-pyrazol-4-yl)-N2-(5-methyloxazol-3-yl)-N4-(piperidin-4-yl)-2,4-diaminopyrimidine,
5-(thien-2-yl)-N2-(5-methylpyrazol-3-yl)-N4-(piperidin-4-yl)-2,4-diaminopyrimidine,
5-(thien-2-yl)-N2-(5-methyloxazol-3-yl)-N4-(piperidin-4-yl)-2,4-diaminopyrimidine,
5-(furan-2-yl)-N2-(5-methylpyrazol-3-yl)-N4-(piperidin-4-yl)-2,4-diaminopyrimidine, and
5-(furan-2-yl)-N2-(5-methyloxazol-3-yl)-N4-(piperidin-4-yl)-2,4-diaminopyrimidine.

### Claim at position 6 (depends on 3)

6: The 2-substituted aromatic ring-pyrimidine derivative, and the optical isomer or the pharmaceutically acceptable salt or the solvate thereof, as recited in claim 3, wherein the 2-substituted aromatic ring-pyrimidine derivative has a structure as shown in a general formula V:
wherein W, X, Y and Z are identical or different and are independently selected from N and C;
R1 is selected from halogen atom, C1-6 alkyl, halogenated C1-6 alkyl, C3-6 cycloalkyl, halogenated C3-6 cycloalkyl, C1-6 alkoxy, halogenated C1-6 alkoxy, C2-6 alkenyl, C2-6 hydroxy substituted alkenyl, C2-6 alkynyl, C2-6 hydroxy substituted alkynyl, and an unsubstituted or substituted penta- or hexa- aromatic ring or aromatic heterocyclic ring, wherein the aromatic heterocyclic ring comprises 1 to 3 hetero atoms selected from O, N and S, substitution is mono-, di- or tri-substitution, and a substituent is Ra;
Ra is selected from H, halogen, nitro, cyano, C1-3 alkyl, halogenated C1-3 alkyl, —C(═O)ORb, —C(═O)NHRb, —NHRb, —ORb, and —NHCORb; Rb is selected from H, C1-3 alkyl, halogenated C1-3 alkyl, C1-3 alkoxy, halogenated C1-3 alkoxy, and C1-7 alkylamine;
R2 is selected from H, —NHRc, —N(Rc)2, —ORc, and —SRc; Rc is selected from penta- to octa-aliphatic ring containing 1 to 3 heteroatoms selected from O and N, C1-7 alkyl, C1-7 hydroxyalkyl, C1-7 alkylamino, and C1-7 alkoxy;
R3 is selected from halogen, nitro, cyano, C1-3 alkyl, halogenated C1-3 alkyl, C1-3 alkoxy, halogenated C1-3 alkoxy, C1-3 alkylamino, and halogenated C1-3 alkylamino;
R4 is selected from H, halogen, nitro, cyano, trifluoromethyl, C1-3 alkyl, C1-3 alkoxy, amide, substituted alkyl amide.

### Claim at position 7 (depends on 6)

7: The 2-substituted aromatic ring-pyrimidine derivative, and the optical isomer or the pharmaceutically acceptable salt or the solvate thereof, as recited in claim 6, wherein the derivative is selected from:
5-phenyl-N2-(2-cyanopyridin-5-yl)-N4-(piperidin-4-methyl)-2,4-diaminopyrimidine,
5-(3-fluorophenyl)-N2-(2-cyanopyridin-5-yl)-N4-(piperidin-4-methyl)-2,4-diaminopyrimidine,
5-(1-methyl-1H-pyrazol-4-yl)-N2-(2-cyanopyridin-5-yl)-N4-(piperidin-4-methyl)-2,4-diaminopyrimidine,
5-trifluoromethyl-N2-(2-cyanopyridin-5-yl)-N4-(piperidin-4-methyl)-2,4-diaminopyrimidine,
5-(3-fluorophenyl)-N2-(2-cyanopyridin-5-yl)-N4-aminoethyl-2,4-diaminopyrimidine,
5-(1-methyl-1H-pyrazol-4-yl)-N2-(2-cyanopyridin-5-yl)-N4-aminoethyl-2,4-diaminopyrimidine,
5-(3-fluorophenyl)-N2-(2-cyanopyridin-5-yl)-N4-(2-morpholinethyl)-2,4-diaminopyrimidine,
5-(1-methyl-1H-pyrazol-4-yl)-N2-(2-cyanopyridin-5-yl)-N4-(2-morpholinethyl)-2,4-diaminopyrimidine,
5-(3-fluorophenyl)-N2-(2-cyanopyridin-5-yl)-N4-(piperidin-4-yl)-2,4-diaminopyrimidine,
5-(1-methyl-1H-pyrazol-4-yl)-N2-(2-cyanopyridin-5-yl)-N4-(piperidin-4-yl)-2,4-diaminopyrimidine,
5-(thien-2-yl)-N2-(2-cyanopyridin-5-yl)-N4-(piperidin-4-yl)-2,4-diaminopyrimidine,
5-(furan-2-yl)-N2-(2-cyanopyridin-5-yl)-N4-(piperidin-4-yl)-2,4-diaminopyrimidine,
5-(5-methoxycarbonylthiophen-2-yl)-N2-(2-cyanopyridin-5-yl)-N4-(piperidin-4-yl)-2,4-diaminopyrimidine,
5-(5-methoxycarbonylfuran-2-yl)-N2-(2-cyanopyridin-5-yl)-N4-(piperidin-4-yl)-2,4-diaminopyrimidine,
5-trifluoromethyl-N2-(2-cyanopyridin-5-yl)-N4-(piperidin-4-yl)-2,4-diaminopyrimidine,
(R)-5-(1-methyl-1H-pyrazol-4-yl)-N2-(2-cyanopyridin-5-yl)-N4-(piperidin-3-yl)-2,4-diaminopyrimidine,
(S)-5-(1-methyl-1H-pyrazol-4-yl)-N2-(2-cyanopyridin-5-yl)-N4-(piperidin-3-yl)-2,4-diaminopyrimidine,
(R)-5-trifluoromethyl-N2-(2-cyanopyridin-5-yl)-N4-(piperidin-3-yl)-2,4-diamino pyrimidine,
(R)-5-(1-methyl-1H-pyrazol-4-yl)-N-(2-cyanopyridin-5-yl)-4-(3-aminopiperidin-1-yl)-2-aminopyrimidine,
5-(3-fluorophenyl)-N2-(2-cyanopyrimidin-5-yl)-N4-(2-morpholinethyl)-2,4-diaminopyrimidine,
5-(1-methyl-1H-pyrazol-4-yl)-N2-(2-cyanopyrimidin-5-yl)-N4-(2-morpholinethyl)-2,4-diaminopyrimidine,
5-(1-methyl-1H-pyrazol-4-yl)-N2-(pyridazin-5-yl)-N4-(piperidin-4-yl)-2,4-diaminopyrimidine,
5-(1-methyl-1H-pyrazol-4-yl)-N2-(3-cyanopyridin-6-yl)-N4-(piperidin-4-yl)-2,4-diaminopyrimidine,
5-(1-methyl-1H-pyrazol-4-yl)-N2-(2-cyanopyrazin-5-yl)-N4-(piperidin-4-yl)-2,4-diaminopyrimidine,
5-bromo-N2-(2-cyanopyridin-5-yl)-N4-(piperidin-4-yl)-2,4-diaminopyrimidine,
5-(4-methylthiazol-2-yl)-N2-(2-cyanopyridin-5-yl)-N4-(piperidin-4-yl)-2,4-diaminopyrimidine,
5-bromo-N-(2-cyanopyridin-5-yl)-2-aminopyrimidine,
5-(2-aminophenyl)-N-(2-cyanopyridin-5-yl)-2-aminopyrimidine,
5-(2-(piperidin-4-yl)aminophenyl)-N-(2-cyanopyridin-5-yl)-2-aminopyrimidine,
5-(2-(piperidin-4-methyl)aminophenyl)-N-(2-cyanopyridin-5-yl)-2-aminopyrimidine, and
pharmaceutically acceptable salts or solvates of the above compounds.

### Claim at position 8

8: A preparation method of a 2-substituted aromatic ring-pyrimidine derivative, comprising steps of:
method I:
using 5-bromo-2,4-dichloropyrimidine as a starting material, substituting with an aliphatic amine group and an aromatic heterocyclic amine group in sequence, and obtaining a target compound by Suzuki coupling, followed by deprotecting a Boc protective group;
method II:
using 5-bromo-2,4-dichloropyrimidine as a starting material, substituting with an aliphatic amine group and aminating in sequence to obtain a 5-bromo-pyrimidine-2,4-diamine intermediate, and processing the intermediate with Suzuki coupling before reacting with a brominated aromatic heterocyclic compound to obtain a target compound, followed by deprotecting a Boc protective group;
method III:
using 5-bromo-2,4-dichloropyrimidine as a starting material, substituting with an aliphatic amine group and aminating in sequence to obtain a 5-bromo-pyrimidine-2,4-diamine intermediate, acting the intermediate with a brominated aromatic heterocyclic compound, and then processing with Suzuki coupling and deprotecting a Boc protective group to obtain a target compound;
method IV:
using 5-bromo-2-aminopyrimidine as a starting material, reacting with a brominated aromatic heterocyclic compound before Suzuki coupling, reductive amination and deprotecting a Boc protective group in sequence to obtain a target compound; or
method V:
using 5-trifluoromethyl-2,4-dichloropyrimidine as a starting material, substituting with an aliphatic amine group and aminating in sequence to obtain a 5-trifluoromethyl-pyrimidine-2,4-diamine intermediate, then acting the intermediate with a brominated aromatic heterocyclic compound to obtain a target compound and deprotecting a Boc protective group.

### Claim at position 9

9: A method for preparing antitumor drugs, comprising a step of using a therapeutically effective amount of a 2-substituted aromatic ring-pyrimidine derivative, wherein tumors are breast cancer, ovarian cancer, sarcoma, lung cancer, prostate cancer, colon cancer, rectal cancer, kidney cancer, pancreatic cancer, leukemia, lymphoma, neuroblastoma, glioma, head and neck cancer, thyroid cancer, liver cancer, vulvar cancer, cervical cancer, endometrial cancer, testicular cancer, bladder cancer, esophageal cancer, gastric cancer, nasopharyngeal carcinoma, buccal cancer, oral cancer, gastrointestinal stromal tumor, skin cancer, multiple myeloma, non-Hodgkin's lymphoma; the 2-substituted aromatic ring-pyrimidine derivative comprises an optical isomer or a pharmaceutically acceptable salt or a solvate of the derivative.

### Claim 10

(canceled)
